Company intelligence / Profile preview

NeoTract

Pleasanton, California, United Stateses.urolift.com ↗

Ownership: Private
Employees: ~943
Development stage: Commercial

Overview

The UroLift System developed by NeoTract has been clinically proven in multiple studies—including randomized clinical trials and meta-analysis—to rapidly and effectively treat urinary symptoms of BPH while preserving normal sexual function. It has broad reimbursement coverage in the US and has treated over 60,000 patients globally prior to acquisition[2][4].

Therapeutic areas: Men's Health
Modalities: Device (Implantable transprostatic tissue retractor system)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

UroLift System

Commercial

Indications: Benign prostatic hyperplasia (BPH)

Partnerships

No major external pharma/biotech partnerships disclosed; now integrated with Teleflex’s distribution network[5]

Beyond the preview

Go deeper on NeoTract.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoTract.

Explore the full profile